Your browser doesn't support javascript.
loading
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells.
Sconocchia, Tommaso; Foßelteder, Johannes; Köhnke, Thomas; Majeti, Ravindra; Reinisch, Andreas.
Afiliação
  • Sconocchia T; Division of Hematology, Department of Internal Medicine, Medical University of Graz.
  • Foßelteder J; Division of Hematology, Department of Internal Medicine, Medical University of Graz.
  • Köhnke T; Division of Hematology, Stanford Cancer Institute, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine.
  • Majeti R; Division of Hematology, Stanford Cancer Institute, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine.
  • Reinisch A; Division of Hematology, Department of Internal Medicine, Medical University of Graz; Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz; a.reinisch@medunigraz.at.
J Vis Exp ; (193)2023 03 10.
Article em En | MEDLINE | ID: mdl-36971438
ABSTRACT
Throughout their lifetime, hematopoietic stem and progenitor cells (HSPCs) acquire somatic mutations. Some of these mutations alter HSPC functional properties such as proliferation and differentiation, thereby promoting the development of hematologic malignancies. Efficient and precise genetic manipulation of HSPCs is required to model, characterize, and better understand the functional consequences of recurrent somatic mutations. Mutations can have a deleterious effect on a gene and result in loss-of-function (LOF) or, in stark contrast, may enhance function or even lead to novel characteristics of a particular gene, termed gain-of-function (GOF). In contrast to LOF mutations, GOF mutations almost exclusively occur in a heterozygous fashion. Current genome-editing protocols do not allow for the selective targeting of individual alleles, hampering the ability to model heterozygous GOF mutations. Here, we provide a detailed protocol on how to engineer heterozygous GOF hotspot mutations in human HSPCs by combining CRISPR/Cas9-mediated homology-directed repair and recombinant AAV6 technology for efficient DNA donor template transfer. Importantly, this strategy makes use of a dual fluorescent reporter system to allow for the tracking and purification of successfully heterozygously edited HSPCs. This strategy can be employed to precisely investigate how GOF mutations affect HSPC function and their progression toward hematological malignancies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Edição de Genes / Mutação com Ganho de Função Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Vis Exp Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Edição de Genes / Mutação com Ganho de Função Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Vis Exp Ano de publicação: 2023 Tipo de documento: Article